septic shock. Severe sepsis with septic shock
Conditions
Interventions
Intervention 1: Intervention group: Continuous intravenous infusion group: Patients in this group are treated with 200 mg daily hydrocortisone (Dana Pharmaceutical Company, Tabriz, Iran), diluted in 5
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Age=18 years Diagnosis of septic shock
Exclusion criteria
Exclusion criteria: Long-term use of glucocorticoids more than 5 mg of prednisolone daily (or equivalent) for more than one month prior to admission Receiving dexamethasone or corticosteroid injections at any dose within 24 hours before recruitment Known adrenal or pituitary disorders including Addison's disease, pituitary insufficiency, adrenal tumors Use of hypothalamic-pituitary-adrenal axis-disrupting drugs Sensitivity to hydrocortisone Systemic fungal infection Psychiatric disorders Expected survival time less than 24 hours Simultaneous participation in another clinical trial Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adrenal recovery. Timepoint: Immediately and 48 hours after hydrocortisone discontinuation. Method of measurement: Based on vital signs and hemodynamic parameters and electrolyte status extracted from the patient's records. | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative dose of vasopressor. Timepoint: At the beginning of the study (before the start of the intervention) and then daily for up to 7 days. Method of measurement: Recording the vasopressor dose in the patient's record.;Duration of vasopressor administration. Timepoint: At the beginning of the study (before the start of the intervention) and then daily for up to 7 days. Method of measurement: Recording the time of initiation and discontinuation of the vasopressor in the patient's record.;The time at which the second vasopressor should be added. Timepoint: At the beginning of the study (before the start of the intervention) and then daily for up to 7 days. Method of measurement: Patient follow-up and recording the time of initiation of the vasopressor in the patient's record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParinaz Sadat Mahmoudi
Tehran University of Medical Sciences
Outcome results
None listed